Matching articles for "COPD"
Issue 1735 · August 18, 2025
Mepolizumab (Nucala) for COPD

Mepolizumab ( Nucala – GSK), a subcutaneously injected interleukin-5 (IL-5) antagonist, has been approved by the FDA for add-on maintenance treatment of adults who have inadequately controlled chronic…

Med Lett Drugs Ther. 2025 Aug 18; 67(1735):131-2 doi:10.58347/tml.2025.1735b
Mepolizumab ( Nucala – GSK), a subcutaneously injected interleukin-5 (IL-5) antagonist, has been approved by the FDA for add-on maintenance treatment of adults who have inadequately controlled chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype. Mepolizumab is also approved for treatment of asthma, chronic rhinosinusitis with nasal polyps, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome.
Issue 1720 · January 20, 2025
Dupilumab (Dupixent) for COPD

The FDA has approved the subcutaneously injected interleukin (IL)-4 receptor alpha antagonist dupilumab ( Dupixent – Sanofi/Regeneron) for add-on maintenance treatment of adults with inadequately controlled…

Med Lett Drugs Ther. 2025 Jan 20; 67(1720):11-3 doi:10.58347/tml.2025.1720c
The FDA has approved the subcutaneously injected interleukin (IL)-4 receptor alpha antagonist dupilumab ( Dupixent – Sanofi/Regeneron) for add-on maintenance treatment of adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. Dupilumab is the first biologic drug to be approved in the US for this indication. It has been available for years for treatment of asthma, atopic dermatitis, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, and prurigo nodularis.
Issue 1710 · September 2, 2024
Drugs for COPD

The main goals of treatment of chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, prevent disease progression, and reduce mortality. GOLD…

Med Lett Drugs Ther. 2024 Sep 2; 66(1710):137-44 doi:10.58347/tml.2024.1710a
The main goals of treatment of chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, prevent disease progression, and reduce mortality. GOLD (Global Initiative for Chronic Obstructive Lung Disease) guidelines for treatment of COPD were updated recently. Treatment of acute exacerbations is not discussed here. Drugs available for treatment of COPD are listed in Tables 1 and 3.
Issue 1710 · September 2, 2024
Comparison Table: Inhaled Drugs for Treatment of COPD (online only)

View the Comparison Table: Inhaled Drugs for Treatment of COPD

Med Lett Drugs Ther. 2024 Sep 2; 66(1710):e143-7 doi:10.58347/tml.2024.1710b
View the Comparison Table: Inhaled Drugs for Treatment of COPD
Issue 1709 · August 19, 2024
Ensifentrine (Ohtuvayre) for COPD

The FDA has approved ensifentrine ( Ohtuvayre – Verona), an inhaled phosphodiesterase (PDE) 3 and 4 inhibitor, for maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults. It is the…

Med Lett Drugs Ther. 2024 Aug 19; 66(1709):131-3 doi:10.58347/tml.2024.1709b
The FDA has approved ensifentrine ( Ohtuvayre – Verona), an inhaled phosphodiesterase (PDE) 3 and 4 inhibitor, for maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults. It is the first dual inhibitor of PDE3 and PDE4 to be approved by the FDA, and the first inhaled drug with a new mechanism of action to be approved for treatment of COPD in more than 20 years.
Issue 1709 · August 19, 2024
Ryzneuta for Prevention of Febrile Neutropenia

Efbemalenograstim alfa-vuxw ( Ryzneuta – Evive), a nonpegylated granulocyte colony-stimulating factor (G-CSF) conjugated to an Fc fragment of human IgG2, has been approved by the FDA to decrease the…

Med Lett Drugs Ther. 2024 Aug 19; 66(1709):134-5 doi:10.58347/tml.2024.1709d
Efbemalenograstim alfa-vuxw ( Ryzneuta – Evive), a nonpegylated granulocyte colony-stimulating factor (G-CSF) conjugated to an Fc fragment of human IgG2, has been approved by the FDA to decrease the incidence of infection, as manifested by febrile neutropenia, in adults with nonmyeloid malignancies receiving myelosuppressive chemotherapy that can cause clinically significant febrile neutropenia. It is the first nonpegylated, long-acting G-CSF to become available in the US. Two pegylated, long-acting G-CSFs, pegfilgrastim ( Neulasta , and biosimilars) and eflapegrastim (Rolvedon) , are also available.
Issue 1606 · September 7, 2020
Drugs for COPD

The main goals of treatment for chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, and prevent disease progression. Several guidelines and…

Med Lett Drugs Ther. 2020 Sep 7; 62(1606):137-44
The main goals of treatment for chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, and prevent disease progression. Several guidelines and review articles on COPD treatment have been published in recent years. Treatment of acute exacerbations is not discussed here.
Issue 1606 · September 7, 2020
Comparison Table: Inhaled Long-Acting Bronchodilators for Treatment of COPD (online only)

View the Comparison Table: Inhaled Long-Acting Bronchodilators for Treatment of COPD

Med Lett Drugs Ther. 2020 Sep 7; 62(1606):e146-7
View the Comparison Table: Inhaled Long-Acting Bronchodilators for Treatment of COPD
Issue 1606 · September 7, 2020
Comparison Table: Inhaled Corticosteroids for Treatment of COPD (online only)

View the Comparison Table: Inhaled Corticosteroids for Treatment of COPD

Med Lett Drugs Ther. 2020 Sep 7; 62(1606):e148-9
View the Comparison Table: Inhaled Corticosteroids for Treatment of COPD
Issue 1606 · September 7, 2020
Table: Correct Use of Inhalers for COPD (online only)

View the Table: Correct Use of Inhalers for COPD

Med Lett Drugs Ther. 2020 Sep 7; 62(1606):e150-4
View the Table: Correct Use of Inhalers for COPD
Issue 1606 · September 7, 2020
Comparison Table: Inhaled Short-Acting Bronchodilators for Treatment of COPD (online only)

View the Comparison Table: Inhaled Short-Acting Bronchodilators for Treatment of COPD

Med Lett Drugs Ther. 2020 Sep 7; 62(1606):e144-5
View the Comparison Table: Inhaled Short-Acting Bronchodilators for Treatment of COPD
Issue 1599 · June 1, 2020 Free
In Brief: Respiratory Depression with Gabapentinoids

The FDA has required new warnings in the labels of gabapentin ( Neurontin , and others) and pregabalin ( Lyrica , Lyrica CR , and generics) about the risk of life-threatening or fatal respiratory depression in…

Med Lett Drugs Ther. 2020 Jun 1; 62(1599):81
The FDA has required new warnings in the labels of gabapentin ( Neurontin , and others) and pregabalin ( Lyrica , Lyrica CR , and generics) about the risk of life-threatening or fatal respiratory depression in patients with respiratory risk factors. Respiratory risk factors include chronic obstructive pulmonary disease (COPD) and concurrent use of opioids or other CNS depressants. Elderly patients are also at increased risk.
Issue 1581 · September 23, 2019
Duaklir Pressair: Another LAMA/LABA Inhaler for COPD

The FDA has approved Duaklir Pressair (Circassia), a fixed-dose combination of the long-acting muscarinic antagonist (LAMA) aclidinium bromide and the longacting beta 2 -adrenergic agonist (LABA) formoterol…

Med Lett Drugs Ther. 2019 Sep 23; 61(1581):149-51
The FDA has approved Duaklir Pressair (Circassia), a fixed-dose combination of the long-acting muscarinic antagonist (LAMA) aclidinium bromide and the longacting beta 2 -adrenergic agonist (LABA) formoterol fumarate, for maintenance treatment of chronic obstructive pulmonary disease (COPD). Aclidinium/formoterol is the fifth LAMA/LABA combination to be approved in the US for this indication.
Issue 1564 · January 28, 2019
Revefenacin (Yupelri) for COPD

The FDA has approved revefenacin ( Yupelri – Mylan/Theravance Biopharma), a long-acting antimuscarinic agent (LAMA) administered once daily by standard jet nebulizer, for maintenance treatment of chronic…

Med Lett Drugs Ther. 2019 Jan 28; 61(1564):14-5
The FDA has approved revefenacin ( Yupelri – Mylan/Theravance Biopharma), a long-acting antimuscarinic agent (LAMA) administered once daily by standard jet nebulizer, for maintenance treatment of chronic obstructive pulmonary disease (COPD). Revefenacin is the second nebulized LAMA to be approved for this indication; glycopyrrolate (Lonhala Magnair) , which is administered twice daily with a portable handheld nebulizer, was the first.
Issue 1547 · May 21, 2018
Trelegy Ellipta - A Three-Drug Inhaler for COPD

The FDA has approved Trelegy Ellipta (GSK), a fixed-dose combination of the inhaled corticosteroid (ICS) fluticasone furoate, the long-acting antimuscarinic agent (LAMA) umeclidinium, and the long-acting beta…

Med Lett Drugs Ther. 2018 May 21; 60(1547):86-8
The FDA has approved Trelegy Ellipta (GSK), a fixed-dose combination of the inhaled corticosteroid (ICS) fluticasone furoate, the long-acting antimuscarinic agent (LAMA) umeclidinium, and the long-acting beta 2 -agonist (LABA) vilanterol. It is available as a dry powder inhaler for once-daily maintenance treatment of COPD and to reduce COPD exacerbations in patients with a history of exacerbations. Trelegy Ellipta is the first three-drug inhaler for treatment of COPD to become available in the US.
Issue 1545 · April 23, 2018
Nebulized Glycopyrrolate (Lonhala Magnair) for COPD

The FDA has approved an inhalation solution formulation of the long-acting antimuscarinic agent (LAMA) glycopyrrolate ( Lonhala Magnair – Sunovion) for maintenance treatment of chronic obstructive pulmonary…

Med Lett Drugs Ther. 2018 Apr 23; 60(1545):72
The FDA has approved an inhalation solution formulation of the long-acting antimuscarinic agent (LAMA) glycopyrrolate ( Lonhala Magnair – Sunovion) for maintenance treatment of chronic obstructive pulmonary disease (COPD). The new formulation is delivered using a portable, handheld, electronic nebulizer. Glycopyrrolate is also available as a dry powder inhaler, both alone (Seebri Neohaler) and in combination with indacaterol (Utibron Neohaler) , and as a metered-dose inhaler in combination with formoterol (Bevespi Aerosphere) . Lonhala Magnair is the first nebulized LAMA to become available in the US.
Issue 1518 · April 10, 2017
Comparison Table: Inhaled Short-Acting Bronchodilators for COPD (online only)

View the Comparison Table: Inhaled Short-Acting Bronchodilators for COPD

Med Lett Drugs Ther. 2017 Apr 10; 59(1518):e62-3
View the Comparison Table: Inhaled Short-Acting Bronchodilators for COPD
Issue 1518 · April 10, 2017
Drugs for COPD

The main goals of treatment for chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, and prevent disease progression. Updated guidelines for…

Med Lett Drugs Ther. 2017 Apr 10; 59(1518):57-62
The main goals of treatment for chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, and prevent disease progression. Updated guidelines for treatment of COPD have been published in recent years.
Issue 1518 · April 10, 2017
Comparison Table: Inhaled Long-Acting Bronchodilators for COPD (online only)

View the Comparison Table: Inhaled Long-Acting Bronchodilators for COPD

Med Lett Drugs Ther. 2017 Apr 10; 59(1518):e64-5
View the Comparison Table: Inhaled Long-Acting Bronchodilators for COPD
Issue 1518 · April 10, 2017
Comparison Table: Some Inhaled Corticosteroids for COPD (online only)

View the Comparison Table: Some Inhaled Corticosteroids for COPD

Med Lett Drugs Ther. 2017 Apr 10; 59(1518):e66
View the Comparison Table: Some Inhaled Corticosteroids for COPD
Issue 1518 · April 10, 2017
Table: Correct Use of Inhalers for COPD (online only)

View the Table: Correct Use of Inhalers for COPD

Med Lett Drugs Ther. 2017 Apr 10; 59(1518):e67-71
View the Table: Correct Use of Inhalers for COPD
Issue 1505 · October 10, 2016
Glycopyrrolate/Formoterol (Bevespi Aerosphere) for COPD

The FDA has approved a fixed-dose combination of the long-acting anticholinergic glycopyrrolate and the long-acting beta 2- adrenergic agonist (LABA) formoterol ( Bevespi Aerosphere – AstraZeneca) for…

Med Lett Drugs Ther. 2016 Oct 10; 58(1505):130-2
The FDA has approved a fixed-dose combination of the long-acting anticholinergic glycopyrrolate and the long-acting beta 2- adrenergic agonist (LABA) formoterol ( Bevespi Aerosphere – AstraZeneca) for long-term maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Glycopyrrolate/formoterol is the fourth long-acting anticholinergic/LABA combination to be approved in the US, but the first to become available in a metered-dose inhaler. Glycopyrrolate/indacaterol (Utibron Neohaler) , umeclidinium/vilanterol (Anoro Ellipta) , and tiotropium/olodaterol (Stiolto Respimat) were approved earlier.
Issue 1496 · June 6, 2016
Alternatives to Fluoroquinolones

The FDA has announced that it is requiring changes in the labeling of systemic fluoroquinolones to warn that the risk of serious adverse effects, including tendinitis, peripheral neuropathy and CNS effects,…

Med Lett Drugs Ther. 2016 Jun 6; 58(1496):75-6
The FDA has announced that it is requiring changes in the labeling of systemic fluoroquinolones to warn that the risk of serious adverse effects, including tendinitis, peripheral neuropathy and CNS effects, generally outweighs their benefit for the treatment of acute sinusitis, acute exacerbations of chronic bronchitis, and uncomplicated urinary tract infections. For these infections, the new labels will recommend reserving fluoroquinolones for patients with no other treatment options.
Issue 1491 · March 28, 2016
Seebri Neohaler and Utibron Neohaler for COPD

The FDA has approved two new inhalers for long-term maintenance treatment of chronic obstructive pulmonary disease (COPD). Seebri Neohaler (Novartis) contains the long-acting anticholinergic glycopyrrolate.…

Med Lett Drugs Ther. 2016 Mar 28; 58(1491):39-41
The FDA has approved two new inhalers for long-term maintenance treatment of chronic obstructive pulmonary disease (COPD). Seebri Neohaler (Novartis) contains the long-acting anticholinergic glycopyrrolate. Utibron Neohaler (Novartis) contains both glycopyrrolate and the long-acting beta 2 -adrenergic agonist (LABA) indacaterol. Glycopyrrolate/indacaterol is the third fixed-dose combination of a long-acting anticholinergic and a LABA to become available in the US; umeclidinium/vilanterol (Anoro Ellipta) and tiotropium/olodaterol (Stiolto Respimat) were approved earlier.
Issue 1482 · November 23, 2015
Tiotropium/Olodaterol (Stiolto Respimat) for COPD

The FDA has approved a fixed-dose, orally inhaled combination of the long-acting anticholinergic tiotropium and the long-acting beta 2 -adrenergic agonist olodaterol ( Stiolto Respimat — Boehringer…

Med Lett Drugs Ther. 2015 Nov 23; 57(1482):161-2
The FDA has approved a fixed-dose, orally inhaled combination of the long-acting anticholinergic tiotropium and the long-acting beta 2 -adrenergic agonist olodaterol ( Stiolto Respimat — Boehringer Ingelheim) for long-term, once-daily, maintenance treatment of airflow obstruction in chronic obstructive pulmonary disease (COPD). It is not approved for treatment of acute exacerbations of COPD or for treatment of asthma. Tiotropium (Spiriva Handihaler , Spiriva Respimat) and olodaterol (Striverdi Respimat) are also available separately for once-daily treatment of COPD.
Issue 1469 · May 25, 2015
Fluticasone Furoate (Arnuity Ellipta) for Asthma

The FDA has approved Arnuity Ellipta (GSK), a single-agent inhaler containing the corticosteroid fluticasone furoate, for once-daily maintenance treatment of asthma in patients ≥12 years old. Fluticasone…

Med Lett Drugs Ther. 2015 May 25; 57(1469):76-9
The FDA has approved Arnuity Ellipta (GSK), a single-agent inhaler containing the corticosteroid fluticasone furoate, for once-daily maintenance treatment of asthma in patients ≥12 years old. Fluticasone furoate is also available in combination with the long-acting beta 2 -agonist vilanterol as Breo Ellipta for treatment of asthma and COPD.
Issue 1467 · April 27, 2015
Umeclidinium (Incruse Ellipta) for COPD

The FDA has approved Incruse Ellipta (GSK), a single-agent inhaler containing the long-acting anticholinergic umeclidinium, for once-daily maintenance treatment of chronic obstructive pulmonary disease (COPD).…

Med Lett Drugs Ther. 2015 Apr 27; 57(1467):63-4
The FDA has approved Incruse Ellipta (GSK), a single-agent inhaler containing the long-acting anticholinergic umeclidinium, for once-daily maintenance treatment of chronic obstructive pulmonary disease (COPD). Umeclidinium was initially approved in combination with the long-acting beta 2 -adrenergic agonist vilanterol as Anoro Ellipta .
Issue 1465 · March 30, 2015
Spiriva Respimat - An Oral Inhalation Spray for COPD

Tiotropium bromide, an inhaled long-acting anticholinergic available since 2004 as a dry powder inhaler (Spiriva Handihaler) for once-daily treatment of chronic obstructive pulmonary disease (COPD), has now…

Med Lett Drugs Ther. 2015 Mar 30; 57(1465):49-50
Tiotropium bromide, an inhaled long-acting anticholinergic available since 2004 as a dry powder inhaler (Spiriva Handihaler) for once-daily treatment of chronic obstructive pulmonary disease (COPD), has now also been approved in an inhalation spray formulation ( Spiriva Respimat – Boehringer Ingelheim). According to the manufacturer, the Respimat device improves delivery of tiotropium to the lungs because, unlike with the Handihaler , it is not dependent on the strength of the patient’s breath intake.
Issue 1459 · January 5, 2015
Olodaterol (Striverdi Respimat) for COPD

Olodaterol ( Striverdi Respimat – Boehringer Ingelheim), a new inhaled long-acting beta 2 -agonist, has been approved by the FDA for once-daily maintenance treatment of airflow obstruction in patients with…

Med Lett Drugs Ther. 2015 Jan 5; 57(1459):1-3
Olodaterol ( Striverdi Respimat – Boehringer Ingelheim), a new inhaled long-acting beta 2 -agonist, has been approved by the FDA for once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). It is not approved for treatment of acute exacerbations of COPD or for treatment of asthma. Olodaterol is the third long-acting beta 2 -agonist to be approved by the FDA for once-daily use; indacaterol (Arcapta Neohaler) , which is available as a single agent, and vilanterol, which is available only in fixed-dose combinations with the long-acting anticholinergic umeclidinium (Anoro Ellipta) or the corticosteroid fluticasone furoate (Breo Ellipta) , were approved earlier.
Issue 1440 · April 14, 2014
Anoro Ellipta: An Inhaled Umeclidinium/Vilanterol Combination for COPD

The FDA has approved an inhaled fixed-dose combination of the long-acting anticholinergic umeclidinium (ue mek" li din' ee um) and the long-acting beta 2 -adrenergic agonist (LABA) vilanterol ( Anoro Ellipta…

Med Lett Drugs Ther. 2014 Apr 14; 56(1440):30-1
The FDA has approved an inhaled fixed-dose combination of the long-acting anticholinergic umeclidinium (ue mek" li din' ee um) and the long-acting beta 2 -adrenergic agonist (LABA) vilanterol ( Anoro Ellipta – GSK/Theravance) for once-daily maintenance treatment of chronic obstructive pulmonary disease (COPD). Anoro Ellipta is the first product available in the US that combines two long-acting bronchodilators in a single delivery device.
Issue 1424 · September 2, 2013
Breo Ellipta: An Inhaled Fluticasone/Vilanterol Combination for COPD

The FDA has approved an inhaled fixed-dose combination ( Breo Ellipta – GSK/Theravance) of the corticosteroid fluticasone furoate and the long-acting beta 2 -adrenergic agonist (LABA) vilanterol trifenatate…

Med Lett Drugs Ther. 2013 Sep 2; 55(1424):69-71
The FDA has approved an inhaled fixed-dose combination ( Breo Ellipta – GSK/Theravance) of the corticosteroid fluticasone furoate and the long-acting beta 2 -adrenergic agonist (LABA) vilanterol trifenatate for once-daily treatment of chronic obstructive pulmonary disease (COPD).
Issue 132 · August 1, 2013
Drugs for Asthma and COPD

INHALATION DEVICES — Metered-dose inhalers (MDIs) require coordination of inhalation with hand-actuation of the device. Valved holding chambers (VHCs) or spacers help some patients, especially young children…

Treat Guidel Med Lett. 2013 Aug; 11(132):75-86
INHALATION DEVICES — Metered-dose inhalers (MDIs) require coordination of inhalation with hand-actuation of the device. Valved holding chambers (VHCs) or spacers help some patients, especially young children and the elderly, use MDIs effectively. VHCs have one-way valves that prevent the patient from exhaling into the device, minimizing the need for coordinated actuation and inhalation. Spacers are tubes or chambers placed between the canister and a face mask or mouthpiece, which also avoids the need to coordinate actuation and inhalation. Both VHCs and spacers retain the larger particles emitted from the MDI, decreasing their deposition in the oropharynx and leading to a higher proportion of small respirable particles being inhaled.
Issue 1389 · April 30, 2012
Indacaterol (Arcapta Neohaler) for COPD

The FDA has approved indacaterol (in´´ da ka´ ter ol; Arcapta Neohaler – Novartis), an inhaled long-acting beta 2 -agonist, for once-daily maintenance treatment of airflow obstruction in patients with…

Med Lett Drugs Ther. 2012 Apr 30; 54(1389):33-5
The FDA has approved indacaterol (in´´ da ka´ ter ol; Arcapta Neohaler – Novartis), an inhaled long-acting beta 2 -agonist, for once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). Indacaterol is not approved for treatment of exacerbations of COPD or for treatment of asthma. It has been available in Europe as Onbrez Breezhaler since 2009.
Issue 1369 · July 25, 2011
Roflumilast (Daliresp) for COPD

Roflumilast ( Daliresp – Forest), an oral phosphodiesterase 4 (PDE4) inhibitor, was approved by the FDA to reduce the risk of exacerbations in adult patients with severe chronic obstructive pulmonary disease…

Med Lett Drugs Ther. 2011 Jul 25; 53(1369):59-60
Roflumilast ( Daliresp – Forest), an oral phosphodiesterase 4 (PDE4) inhibitor, was approved by the FDA to reduce the risk of exacerbations in adult patients with severe chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis and a history of exacerbations.
Issue 99 · November 1, 2010
Drugs for Chronic Obstructive Pulmonary Disease

The goals of drug therapy for chronic obstructive pulmonary disease (COPD) are to reduce symptoms such as dyspnea, improve exercise tolerance and quality of life, and decrease complications of the disease such…

Treat Guidel Med Lett. 2010 Nov; 8(99):83-8
The goals of drug therapy for chronic obstructive pulmonary disease (COPD) are to reduce symptoms such as dyspnea, improve exercise tolerance and quality of life, and decrease complications of the disease such as acute exacerbations. Other guidelines for treatment of this condition have been published or updated in recent years.
Issue 97 · September 1, 2010
Treatment of Atrial Fibrillation

The treatment of atrial fibrillation includes ventricular rate control, anticoagulation, conversion to normal sinus rhythm and maintenance of sinus rhythm. The choice of therapies that can achieve these goals…

Treat Guidel Med Lett. 2010 Sep; 8(97):65-70
The treatment of atrial fibrillation includes ventricular rate control, anticoagulation, conversion to normal sinus rhythm and maintenance of sinus rhythm. The choice of therapies that can achieve these goals is discussed in the text that follows. Some drugs are recommended here for indications that have not been approved by the FDA.
Issue 1339 · May 31, 2010
Safety of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease (COPD)

Two combinations of an inhaled corticosteroid with an inhaled long-acting beta2-agonist are approved by the FDA for use in patients with COPD: fluticasone/salmeterol (Advair Diskus) and budesonide/formoterol…

Med Lett Drugs Ther. 2010 May 31; 52(1339):41-2
Two combinations of an inhaled corticosteroid with an inhaled long-acting beta2-agonist are approved by the FDA for use in patients with COPD: fluticasone/salmeterol (Advair Diskus) and budesonide/formoterol (Symbicort) . A Medical Letter reader has questioned the safety of using corticosteroid inhalers in patients with this disorder. No single-agent inhaled corticosteroid inhaler is approved for this indication.
Issue 73 · September 1, 2008
Drugs for Tobacco Dependence

Peptic ulcers caused by treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) are mainly gastric ulcers. The greater the number of office visits and the longer the counseling time, the higher the…

Treat Guidel Med Lett. 2008 Sep; 6(73):61-5
Peptic ulcers caused by treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) are mainly gastric ulcers. The greater the number of office visits and the longer the counseling time, the higher the smoking cessation rates have been.
Issue 1274 · November 19, 2007
Formoterol (Perforomist) for COPD

Formoterol fumarate ( Perforomist - Dey), a long-acting beta 2 -agonist, was recently approved by the FDA as an inhalation solution for nebulization for maintenance treatment of bronchoconstriction associated…

Med Lett Drugs Ther. 2007 Nov 19; 49(1274):94-5
Formoterol fumarate ( Perforomist - Dey), a long-acting beta 2 -agonist, was recently approved by the FDA as an inhalation solution for nebulization for maintenance treatment of bronchoconstriction associated with chronic obstructive pulmonary disease (COPD). Arformoterol (Brovana) , the (R, R)-enantiomer of formoterol, was approved earlier this year for the same indication.
Issue 63 · November 1, 2007
Drugs for Chronic Obstructive Pulmonary Disease

The goals of drug therapy for chronic obstructive pulmonary disease (COPD) are to reduce symptoms such as dyspnea, improve exercise tolerance and quality of life, and minimize complications of the disease such…

Treat Guidel Med Lett. 2007 Nov; 5(63):95-100
The goals of drug therapy for chronic obstructive pulmonary disease (COPD) are to reduce symptoms such as dyspnea, improve exercise tolerance and quality of life, and minimize complications of the disease such as acute exacerbations and cor pulmonale. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines developed by the World Health Organization and the National Heart, Lung and Blood Institute were updated in 2006. The American Thoracic Society and the European Respiratory Society jointly developed guidelines for COPD in 2004.
Issue 1264 · July 2, 2007
Arformoterol (Brovana) for COPD

Arformoterol tartrate ( Brovana - Sepracor), a singleisomer, long-acting beta 2 -agonist, has been approved by the FDA as an inhalation solution for nebulization for treatment of bronchoconstriction pulmonary…

Med Lett Drugs Ther. 2007 Jul 2; 49(1264):53-5
Arformoterol tartrate ( Brovana - Sepracor), a singleisomer, long-acting beta 2 -agonist, has been approved by the FDA as an inhalation solution for nebulization for treatment of bronchoconstriction pulmonary disease (COPD). Arformoterol is the (R,R)-enantiomer of formoterol (Foradil) , which is available as a powder for inhalation and was recently also approved as a solution for nebulization ( Perforomist - Dey; available fall 2007)
Issue 1183 · May 24, 2004
Tiotropium (Spiriva) for COPD

Tiotropium bromide inhalation powder ( Spiriva HandiHaler - Boehringer Ingelheim), a long-acting anticholinergic agent, has been approved by the FDA for once-daily maintenance treatment of bronchospasm…

Med Lett Drugs Ther. 2004 May 24; 46(1183):41-2
Tiotropium bromide inhalation powder ( Spiriva HandiHaler - Boehringer Ingelheim), a long-acting anticholinergic agent, has been approved by the FDA for once-daily maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD). Available in Europe since 2002, it is the first long-acting inhaled anticholinergic drug for treatment of COPD. Ipratropium bromide ( Atrovent ), an anticholinergic used four times daily, has been available in the US for many years.